Creative Planning
FOLD

Creative Planning’s Amicus Therapeutics FOLD Stock Holding History

Creative Planning’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.2M Buy
428,977
+26,572
+7% +$381K ﹤0.01% 1025
2025
Q4 		$5.73M Buy
402,405
+21,382
+6% +$210K ﹤0.01% 911
2025
Q3 		$3M Buy
381,023
+164,744
+76% +$1.17M ﹤0.01% 1226
2025
Q2 		$1.24M Buy
216,279
+180,652
+507% +$1.17M ﹤0.01% 1678
2025
Q1 		$291K Sell
35,627
-49,883
-58% -$462K ﹤0.01% 2782
2024
Q4 		$806K Buy
85,510
+32,655
+62% +$339K ﹤0.01% 1826
2024
Q3 		$564K Buy
52,855
+23,433
+80% +$255K ﹤0.01% 1987
2024
Q2 		$292K Sell
29,422
-4,502
-13% -$46.2K ﹤0.01% 2372
2024
Q1 		$400K Buy
33,924
+9,022
+36% +$115K ﹤0.01% 2025
2023
Q4 		$353K Buy
24,902
+7,952
+47% +$90.3K ﹤0.01% 1977
2023
Q3 		$206K Buy
16,950
+2,937
+21% +$37.9K ﹤0.01% 2221
2023
Q2 		$176K Buy
+14,013
New +$166K ﹤0.01% 2244
2017
Q4 		– Sell
-10,343
Closed -$156K – 1942
2017
Q3 		$156K Buy
10,343
+70
+0.7% +$926 ﹤0.01% 1656
2017
Q2 		$103K Sell
10,273
-6,127
-37% -$49.3K ﹤0.01% 1973
2017
Q1 		$117K Buy
16,400
+5,900
+56% +$37.3K ﹤0.01% 1849
2016
Q4 		$52K Buy
10,500
+400
+4% +$2.77K ﹤0.01% 2357
2016
Q3 		$75K Hold
10,100
– – ﹤0.01% 2052
2016
Q2 		$55K Sell
10,100
-10,000
-50% -$69.9K ﹤0.01% 2077
2016
Q1 		$170K Buy
20,100
+10,000
+99% +$70.8K ﹤0.01% 1295
2015
Q4 		$98K Buy
+10,100
New +$91K ﹤0.01% 1639
2015
Q1 		– Sell
-1,200
Closed -$10K – 4278
2014
Q4 		$10K Sell
1,200
-300
-20% -$2.06K ﹤0.01% 3116
2014
Q3 		$9K Buy
+1,500
New +$7.86K ﹤0.01% 2995

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Creative Planning's FOLD Position: Q1 2026 in Review

Creative Planning increased its Amicus Therapeutics (FOLD) stake by 6.6% in Q1 2026, buying an estimated $381K and bringing the position to 428,977 shares worth $6.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1025.

Creative Planning first reported a position in FOLD in Q3 2014 and has held it in 22 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Creative Planning held 428,977 shares of Amicus Therapeutics worth $6.2M as of Q1 2026.
  • Creative Planning bought 26,572 Amicus Therapeutics shares in Q1 2026, an estimated $381K.
  • Amicus Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1025 holding.
  • Creative Planning first reported a position in Amicus Therapeutics in Q3 2014 and has held it in 22 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.